Structure Therapeutics (NASDAQ:GPCR) Trading Down 3% - Here's What Happened

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s stock price fell 3% during mid-day trading on Tuesday . The stock traded as low as $22.44 and last traded at $22.42. 312,175 shares changed hands during trading, a decline of 65% from the average session volume of 903,849 shares. The stock had previously closed at $23.10.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GPCR. Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Tuesday. Finally, William Blair started coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Stock Up 0.4 %

The company has a market cap of $1.36 billion, a price-to-earnings ratio of -32.08 and a beta of -1.35. The firm has a 50 day moving average price of $20.17 and a two-hundred day moving average price of $27.78.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, equities analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GPCR. Geode Capital Management LLC grew its holdings in Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock worth $1,985,000 after acquiring an additional 312 shares during the period. Virtus ETF Advisers LLC grew its stake in Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the period. ANTIPODES PARTNERS Ltd increased its holdings in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares in the last quarter. LPL Financial LLC lifted its stake in Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares during the period. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of Structure Therapeutics by 12.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after buying an additional 843 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.